The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor C.
Tumor metastasis to lymph nodes:
Lymph node metastasis is very often associated with several types of human malignancies. Cancer cells’ journey to lymph node largely takes place through lymphatic tunnel located in and around of primary tumor. VEGF-D’s interactions with VEGFR-3 predominantly expressed in lymphatic vessels plays a key role in restructuring lymphatic channel and hence able alter its functions related to fluid and cell transport along the conduits. VEGF-D has been established to be over-expressed in both tumor tissues and patients’ serum samples in several types of human cancer. In addition, VEGF-D expression has been implicated with increased incidence of regional lymph node metastasis. In experimental mice study, genetically modified tumor cell that was forced to produce VEGF-D protein have been established to boost up regional lymph nodes metastases.
Orlandini M, Marconcini L, Ferruzzi R, Oliviero S (1996). "Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family". Proc. Natl. Acad. Sci. U.S.A.93 (21): 11675–80. doi:10.1073/pnas.93.21.11675. PMC38117. PMID8876195.
Yamada Y, Nezu J, Shimane M, Hirata Y (1997). "Molecular cloning of a novel vascular endothelial growth factor, VEGF-D". Genomics42 (3): 483–8. doi:10.1006/geno.1997.4774. PMID9205122.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
Achen MG, Jeltsch M, Kukk E et al. (1998). "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)". Proc. Natl. Acad. Sci. U.S.A.95 (2): 548–53. doi:10.1073/pnas.95.2.548. PMC18457. PMID9435229.
Rocchigiani M, Lestingi M, Luddi A et al. (1998). "Human FIGF: cloning, gene structure, and mapping to chromosome Xp22.1 between the PIGA and the GRPR genes". Genomics47 (2): 207–16. doi:10.1006/geno.1997.5079. PMID9479493.
Stacker SA, Stenvers K, Caesar C et al. (1999). "Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers". J. Biol. Chem.274 (45): 32127–36. doi:10.1074/jbc.274.45.32127. PMID10542248.
Strausberg RL, Feingold EA, Grouse LH et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A.99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC139241. PMID12477932.
Nakamura Y, Yasuoka H, Tsujimoto M et al. (2003). "Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up". Clin. Cancer Res.9 (2): 716–21. PMID12576440.
Yokoyama Y, Charnock-Jones DS, Licence D et al. (2003). "Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma". Br. J. Cancer88 (2): 237–44. doi:10.1038/sj.bjc.6600701. PMC2377043. PMID12610509.
Rissanen TT, Markkanen JE, Gruchala M et al. (2003). "VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses". Circ. Res.92 (10): 1098–106. doi:10.1161/01.RES.0000073584.46059.E3. PMID12714562.
Funaki H, Nishimura G, Harada S et al. (2003). "Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma". Oncology64 (4): 416–22. doi:10.1159/000070301. PMID12759540.
Orlandini M, Semboloni S, Oliviero S (2004). "Beta-catenin inversely regulates vascular endothelial growth factor-D mRNA stability". J. Biol. Chem.278 (45): 44650–6. doi:10.1074/jbc.M304255200. PMID12920128.
Gerhard DS, Wagner L, Feingold EA et al. (2004). "The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC)". Genome Res.14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC528928. PMID15489334.
Kurahara H, Takao S, Maemura K et al. (2005). "Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis". Clin. Cancer Res.10 (24): 8413–20. doi:10.1158/1078-0432.CCR-04-0379. PMID15623620.
Fink AM, Kaltenegger I, Schneider B et al. (2005). "Serum level of VEGF-D in patients with primary lymphedema". Lymphology37 (4): 185–9. PMID15693535.
Kaushal V, Mukunyadzi P, Dennis RA et al. (2005). "Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease". Clin. Cancer Res.11 (2 Pt 1): 584–93. PMID15701844.
Yasuoka H, Nakamura Y, Zuo H et al. (2005). "VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma". Mod. Pathol.18 (8): 1127–33. doi:10.1038/modpathol.3800402. PMID15803188.